Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $32 is 67.51% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 34.09||$ 38.69|
|Low:||$ 31.51||$ 19.1033|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal, or GI, diseases and disorders. The initial target indication for our lead product candidate, A4250, is progressive familial intrahepatic cholestasis, or PFIC, a rare, life-threatening genetic disorder affecting young children for which there is currently no approved drug treatment. We completed a Phase 2 clinical trial of A4250 in children with chronic cholestasis and pruritus, and in May of 2018 we enrolled the first patient in our Phase 3 clinical trial for A4250 in patients with PFIC, which we refer to as PEDFIC 1. In June of 2018, the FDA granted a rare pediatric disease designation to A4250 for the treatment of PFIC, which affirms our eligibility to apply for a rare pediatric disease priority review voucher upon submission of a new drug application for A4250. ... More ...
Nasdaq Official Price
Jun. 19, 2019
Jun. 19, 2019